alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
This  schedule  contains  summary  financial   information  extracted  from  the
condensed  consolidated balance sheet of Dictaphone  Corporation at December 31,
1998 and the condensed  consolidated  statement of operations for the year ended
December  31,  1998  and is  qualified  in its  entirety  by  reference  to such
financial statements.
</LEGEND>
<MULTIPLIER>                            1
       
<S>                             <C>
<PERIOD-TYPE>                           12-MOS
<FISCAL-YEAR-END>                  Dec-31-1998
<PERIOD-START>                     Jan-01-1998
<PERIOD-END>                       Dec-31-1998
<CASH>                                  11,727
<SECURITIES>                                 0
<RECEIVABLES>                           78,400
<ALLOWANCES>                               968
<INVENTORY>                             53,362
<CURRENT-ASSETS>                       150,103
<PP&E>                                  67,188
<DEPRECIATION>                          34,763
<TOTAL-ASSETS>                         454,256
<CURRENT-LIABILITIES>                   99,011
<BONDS>                                369,737
<PREFERRED-MANDATORY>                   23,915
<PREFERRED>                                  0
<COMMON>                                   130
<OTHER-SE>                            (52,607)
<TOTAL-LIABILITY-AND-EQUITY>           454,256
<SALES>                                244,393
<TOTAL-REVENUES>                       332,318
<CGS>                                  188,688
<TOTAL-COSTS>                          345,688
<OTHER-EXPENSES>                             0
<LOSS-PROVISION>                             0
<INTEREST-EXPENSE>                      39,715
<INCOME-PRETAX>                       (52,812)
<INCOME-TAX>                             (878)
<INCOME-CONTINUING>                   (53,690)
<DISCONTINUED>                               0
<EXTRAORDINARY>                              0
<CHANGES>                                    0
<NET-INCOME>                          (53,690)
<EPS-PRIMARY>                                0
<EPS-DILUTED>                                0
        



</TABLE>
### Flood inundation and effects of urbanization in metropolitan Charlotte, North Carolina

By: Lawrence A. Martens

                            https://doi.org/10.3133/wsp1591C

#### Links

-                                                                                                                             Document:                                                                                                                                                                                                                                                  **Report**                                                                                                     (pdf)                                                                                                                                     
- Plates:                               - **Plate 1**                            (pdf)
  - **Plate 2**                            (pdf) 
- NGMDB Index Page:  **National Geologic Map Database Index Page**                            (html)
- Download citation as:  RIS                         |                         Dublin                            Core

#### Abstract

No abstract available. 

#### Study Area

Part or all of this report is presented in Portable Document Format                        (PDF). For best results viewing and printing PDF documents, it is recommended that you download                        the documents to your computer and open them with Adobe Reader. PDF documents opened from your                        browser may not display or print as intended. Download the latest version of Adobe Reader, free of charge. More information                        about viewing, downloading, and printing report files can be found at the common download problems FAQ.
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.5620 *Alpha*-2-macroglobulin immunological test system. ( a ) *Identification.* An *alpha*-2-macroglobulin immunological test system is a device that consists of the reagents used to measure by immunochemical techniques the *alpha*-2-macroglobulin (a serum protein) in plasma. Measurement of *alpha*-2-macroglobulin may aid in the diagnosis of blood-clotting or clot lysis disorders.
( b ) *Classification.* Class II (special controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 866.9.
[47 FR 50823, Nov. 9, 1982, as amended at 84 FR 71800, Dec. 30, 2019]
\ RECEIVEU

SEP 30 2015 m THE untje!) STATES DISTRICT COURT

COURT OF APPEALS FOR THE DISTRICT OF TEXAS

«WND DISTRICT OF TEW, DIVISION pn ,. SDEBRA SP1SAK, CLERK SeCg$*To^p

fternu ^ hel aho yfc^o\<\ tisi | ^JnH^^

Plaintiff's name and ID Number 3 ft Mig

CoFFt-\LO ma \t oes^4* '

3LL\ \-M365H Tcnne$SccCobuy To<«5 A*>CLfz

Place of Confinement ' ~7$?8H **

CASENO. ^I^^r-C

(Clerk will assign the number)

DlVfv^ » „ I- /x ^ \ ,\ o ,htv APPLICATION TO PROCEED tOV**- oatsfbliCt 0^>C-4rn«i^fovv644lX. IN FORMA PAUPERIS

Defendant's name and address

I, nrrn^tf (jgJfiGrl 6 Cffi-. declare, depose, and say I am the Plaintiff in the above entitled case. In support ofmy motion to proceed wrdiout being required to prepay fees, costs, or give security therefor, Istate because ofmy

poverty, I am unable to pay in advance the filing fee for said proceedings or to give security for the filing fee. I believe I

am entitled to relief.

I, further declare the responses which I have made to the questions and instructions below are true.

1. Have you received, within the last 12 months, any money from any of the following sources?

a. Business, profession or from self-employment? Yes Q No 5fl.

b. Rent payments, interest or dividends?. Yes • No So

c. Pensions, annuities or life insurance payments? Yes • No 0j

d. Gifts or inheritances? Yes • No 0

e. Family orfriends? Yes f\jf No Q .

f. Anyother sources? Yes • No \$/

If you answeredYES to any of the questions above,describeeach source of money and state

the amount received from each during the past 12 months.

'-f

2. Doyou own cash, or do you have money in a checking or savings account, including any funds

in prison accounts? t

Yes 0 No D

If you answered YES to any of the questions above, state the total value of the items owned.

rATCIFP (REV. 9/02)
3. Do you own real estate, stocks, bonds, note, automobiles, or other valuable property, excluding

ordinary household furnishings and clothing?

Yes • No

If you answered YES, describe the property and state its approximate value.

I understand a false statement in answer to any question in this affidavit will subject me to penalties for

perjury. I declare (certify, verify, or state) under penalty of perjury that the foregoing is true and correct

(28 U.S.C. §1746).

Signed this the ^^ dav of o<jp r<u^ o€/*" ,20 \$_.

Signature ofPlaintiff u 7 ID Number
§ 74.2317 D&C Red No. 17. ( a ) *Identity and specifications.* The color additive D&C Red No. 17 shall conform in identity and specifications to the requirements of § 74.1317(a)(1) and (b).
( b ) *Uses and restrictions.* D&C Red No. 17 may be safely used for coloring externally applied cosmetics in amounts consistent with good manufacturing practice.
( c ) *Labeling.* The label of the color additive shall conform to the requirements of § 70.25 of this chapter.
( d ) *Certification.* All batches of D&C Red No. 17 shall be certified in accordance with regulations in part 80 of this chapter.
# C_2016200EN.01001901.xml

| 6.6.2016 | EN | Official Journal of the European Union | C 200/19 |
| --- | --- | --- | --- |

6.6.2016

EN

Official Journal of the European Union

C 200/19

---

Judgment of the General Court of 19 April 2016 — Costantini and Others v Commission

(Case T-44/14) (1)

1

((Law governing the institutions - European citizens’ initiative - Social policy - Service of general economic interest - Article 352 TFEU - Refusal of registration - Manifest lack of powers of the Commission - Article 4(2)(b) of Regulation (EU) No 211/2011 - Principle of good administration - Obligation to state reasons))

(2016/C 200/27)

Language of the case: English

Parties

Parties

Applicants: Bruno Costantini (Jesi, Italy), Robert Racke (Lamadelaine, Luxembourg), Pietro Pravata (Beyne-Heusay, Belgium), Zbigniew Gałązka (Łódź, Poland), Justo Santos Domínguez (Leganés, Spain), Maria Isabel Lemos (Mealhada, Portugal), André Clavelou (Vincennes, France), Citizens’ Committee ‘Right to Lifelong Care: Leading a life of dignity and independence is a fundamental right!’ (Brussels, Belgium) (represented by: O. Brouwer and J. Wolfhagen, lawyers, and A. Woods, Solicitor)

Applicants:

Defendant: European Commission (represented by: H. Krämer, acting as Agent)

Defendant:

Re:

Re:

Application for the annulment of Commission Decision C(2013) 7612 final of 5 November 2013 rejecting the request for registration of the proposed European citizens’ initiative entitled ‘Right to Lifelong Care: Leading a life of dignity and independence is a fundamental right!’.

Operative part of the judgment

Operative part of the judgment

The Court:

| 1. | Dismisses the action; |
| --- | --- |

1.

Dismisses the action;

| 2. | Orders Bruno Costantini and the other applicants, whose names are set out in the annex, to pay the costs. |
| --- | --- |

2.

Orders Bruno Costantini and the other applicants, whose names are set out in the annex, to pay the costs.

---

(1)  OJ C 93, 29.3.2014.

1

---
<TABLE> <S> <C>


<ARTICLE> 5
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1996
<PERIOD-START>                             JAN-31-1996
<PERIOD-END>                               SEP-30-1996
<CASH>                                      10,920,648
<SECURITIES>                                49,981,280
<RECEIVABLES>                               10,828,412
<ALLOWANCES>                                         0
<INVENTORY>                                  5,764,508
<CURRENT-ASSETS>                            79,902,904
<PP&E>                                         763,799
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                              81,092,533
<CURRENT-LIABILITIES>                        6,805,411
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                       191,448
<OTHER-SE>                                  74,095,674
<TOTAL-LIABILITY-AND-EQUITY>                81,092,533
<SALES>                                     61,315,223
<TOTAL-REVENUES>                            61,315,223
<CGS>                                       24,798,655
<TOTAL-COSTS>                               22,185,405
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                             15,867,825
<INCOME-TAX>                                 5,825,000
<INCOME-CONTINUING>                         10,042,825
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                10,042,825
<EPS-PRIMARY>                                     0.51
<EPS-DILUTED>                                     0.51
        


</TABLE>
§ 82.3 Definitions. For the purposes of this part: ( a ) - ( f ) [Reserved]
( g ) The term *alumina* means a suspension in water of precipitated aluminum hydroxide.
( h ) The term *blanc fixe* means a suspension in water of precipitated barium sulfate.
( i ) The term *gloss white* means a suspension in water of co-precipitated aluminum hydroxide and barium sulfate.
( j ) The term *mixed oxides* means the sum of the quantities of aluminum, iron, calcium, and magnesium (in whatever combination they may exist in a coal-tar color) calculated as aluminum trioxide, ferric oxide, calcium oxide, and magnesium oxide.
( k ) - ( m ) [Reserved]
( n ) The term *externally applied drugs and cosmetics* means drugs and cosmetics which are applied only to external parts of the body and not to the lips or any body surface covered by mucous membrane.
( o ) - ( p ) [Reserved]
( q ) The definitions and interpretations of terms contained in section 201 of the Federal Food, Drug, and Cosmetic Act shall be applicable also to such terms when used in this part.
<TABLE> <S> <C>

<ARTICLE> 5

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-END>                               MAR-31-2000
<CASH>                                           1,066
<SECURITIES>                                     2,929
<RECEIVABLES>                                    7,100
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                11,095
<PP&E>                                          43,408
<DEPRECIATION>                                  20,786
<TOTAL-ASSETS>                                  33,717
<CURRENT-LIABILITIES>                          596,979
<BONDS>                                              0
<PREFERRED-MANDATORY>                          739,696
<PREFERRED>                                     28,923
<COMMON>                                    21,297,570
<OTHER-SE>                                   (563,262)
<TOTAL-LIABILITY-AND-EQUITY>                    33,717
<SALES>                                              0
<TOTAL-REVENUES>                                     0
<CGS>                                                0
<TOTAL-COSTS>                                    5,926
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                      0
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                         0
<EPS-BASIC>                                          0
<EPS-DILUTED>                                   (0.01)


</TABLE>
#### § 822.8 When, where, and how must I submit my postmarket surveillance plan?

You must submit your plan to conduct postmarket surveillance within 30 days of the date you receive the postmarket surveillance order. For devices regulated by the Center for Biologics Evaluation and Research, send your submission to the Food and Drug Administration, Center for Biologics Evaluation and Research, Document Control Center, 10903 New Hampshire Ave., Bldg. 71, Rm. G112, Silver Spring, MD 20993-0002. For devices regulated by the Center for Drug Evaluation and Research, send your submission to the Central Document Room, Center for Drug Evaluation and Research, Food and Drug Administration, 5901-B, Ammendale Rd., Beltsville, MD 20705-1266. For devices regulated by the Center for Devices and Radiological Health, send your submission to the Document Mail Center, 10903 New Hampshire Ave., Bldg. 66, Rm. G609, Silver Spring, MD 20993-0002. When we receive your original submission, we will send you an acknowledgment letter identifying the unique document number assigned to your submission. You must use this number in any correspondence related to this submission.

[87 FR 17950, Mar. 29, 2022]
# Cope 

# Law Firm 9284 Huntington

Square,

Suite 100 

### North Richland

Hills. 

### Texas

### 76182 (817) 

### 498-2300 (877) 

### 993-3529 (toll free) (817) 

### 581-1500

(facsimile) John

J. Cope jcope(a'coQefirn1.co1n June 26. 

### 2015 Via 

### E-File Clerk 

### ofthe

12"‘ 

### Court 

### of 

### Appeals 1517 

### West Front

Street,

Suite 

### 354 Tyler, 

### Texas 

### 75702 RE: Court



### of 

### Appeals



### Number:

12—15—00169—CV Trial 

### Court 

### Case 

### Number:



### 2012A-0662
Style: 

### Earl



### Anderson,

Carrie

Bell Scott, 

### Sharon

Anderson,



### Evance

Anderson,

Bill Burton, Willie



## Mae Anderson,



### and JerrjyJ.



### Anderson

(Smith)

v. 

### Robert

Louis 

## Durham

and Frank

L. Zellers,

11] 

# NOTICE 

# OF ADDRESS



# CHANGE

Please

take notice

that the address



### and Contact

information

for 

### John

.1. 

### Cope

attorney

for appellee

is: 

### John

J. 

### Cope Cope 

## Law Firm 

### 9284 Huntington

Square Suite 

### 100 

### North Richland

Hills, 

### Texas 

### 76182 Phone:

(817) 

### 498-2300 Fax: 

### (817)581-1500 Email: 

### jc0pe@copefirm.com Please 

### do not hesitate

to Contact 

## me with 

### any questions

or concerns.

.l.lC/am

cc: Lana

Johnson via

email:

l1']atty4(matLnet ACCEPTED 12-15-00169CV TWELFTH COURT OF APPEALS

TYLER, TEXAS 6/29/2015 3:59:08 PM CATHY LUSK CLERK
<PAGE>   1


                                                                     Exhibit 5.1

Nutraceutix, Inc.
8340 - 154th Avenue N.E.
Redmond, Washington 98052



RE:  2,982,000  SHARES OF COMMON STOCK ($.001 PAR VALUE PER SHARE) OF
     NUTRACEUTIX, INC. (THE "COMPANY")

Ladies and Gentlemen:

We have acted as counsel to you in connection with the preparation of a
Registration Statement on Form S-8 (the "Registration Statement") pursuant to
the Securities Act of 1933, as amended (the "Act"), which you are filing with
the Securities and Exchange Commission with respect to 2,982,000 shares of
Common Stock, $.001 par value per share (the "Shares"), which may be issued
pursuant to the Nutraceutix, Inc. 1995 Amended Stock Option Plan (the "Plan").
We have examined the Registration Statement and such other documents and records
of the Company, as we have deemed relevant and necessary for the purposes of
this opinion.

        Based upon and subject to the foregoing, we are of the opinion that the
Shares that will be issued pursuant to the Plan, upon the due execution by the
Company and the registration by its registrar of the Shares and the issuance
thereof by the Company in accordance with the terms of the Plan, and the receipt
of consideration therefor in accordance with the terms of the Plans, will be
validly issued, fully paid and nonassessable.

        We hereby consent to the filing of this opinion as an exhibit to the
Registration Statement. In giving such consent, we do not admit that we are in
the category of persons whose consent is required under Section 7 of the Act.

                                       Very truly yours,



                                       GARVEY, SCHUBERT & BARER
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.2180 Manual colony counter. ( a ) *Identification.* A manual colony counter is a device intended for medical purposes that consists of a printed grid system superimposed on an illuminated screen. Petri plates containing bacterial colonies to be counted are placed on the screen for better viewing and ease of counting. The number of colonies counted is used in the diagnosis of disease as a measure of the degree of bacterial infection.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 866.9. The device is also exempt from the good manufacturing practice requirements of the quality system regulation in part 820 of this chapter, with the exception of § 820.180, with respect to general requirements concerning records, and § 820.198, with respect to complaint files.
[47 FR 50823, Nov. 9, 1982, as amended at 66 FR 38790, July 25, 2001]
#### Kristin M. CASHMAN, Appellee, v. ECONOMY FIRE & CASUALTY COMPANY, Appellant.

No. 85-5429.

United States Court of Appeals, Eighth Circuit.

Submitted June 12, 1986.

Decided July 2, 1986.

Scott T. Anderson, Minneapolis, Minn., for appellant.

Stephen J. Smith, Owatonna, Minn., for appellee.

Before HEANEY and WOLLMAN, Circuit Judges, and BATTEY,* District Judge.

*

 The HONORABLE RICHARD H. BATTEY, United States District Judge for the District of South Dakota, sitting by designation.

PER CURIAM.

Economy Fire and Casualty Company (Economy) appeals from a district court judgment holding that Kristin M. Cashman was insured under policies issued by Economy and awarding Cashman uninsured motorist benefits and prejudgment interest.

On March 15, 1980, Cashman, a passenger in an uninsured vehicle, was injured in an automobile accident in the country of Nigeria. Cashman attempted to recover personal injury protection benefits and uninsured motorist benefits under three insurance policies issued by Economy to Cashman’s mother and two brothers. Economy denied her claim, arguing, in part, that the territorial restriction clause in each policy limited coverage to the United States, its territories or possessions, and Canada.

Cashman filed suit in Minnesota district court against Economy. The state court, in its February 27, 1984, Order and Memorandum, denied Economy’s motion for summary judgment and held that the territorial restriction clause was contrary to Minnesota’s no-fault statute.

Upon removal, the United States District Court for the District of Minnesota, in its Memorandum Order of January 29, 1985, also held that the clause was invalid. It noted that, while at the time of Cashman’s accident the Minnesota no-fault statute re*51quired coverage “[i]f the accident causing injury occurs outside this state,” *see*Minn. Stat. § 65B.46(2) (1978), subsequent to the accident the provision was amended to require coverage “[i]f the accident causing injury occurs outside this state in the United States, United States possessions, or Canada.” Minn.Stat. § 65B.46(2) (1982). It found that, because Economy was unable to rebut the presumption that the amendment was adopted to change existing law, the statute at the time of the accident required coverage of the accident. It also stated that it could not “completely ignore a considered decision by an experienced Judge more familiar with the insurance laws of Minnesota than this court.” Appellant’s Appendix at 24. Following a jury trial, the district court awarded Cashman $150,000 in uninsured motorist benefits and $18,863.01 in prejudgment interest. Economy appeals from this judgment.

“In diversity cases, the district court’s interpretation of the law of the state in which it sits is entitled to great weight or deference.” *Camp v. Commonwealth Land Title Ins. Co.,*787 F.2d 1258, 1260-61 (8th Cir.1986). The two district court judges involved in this matter, as well as the state court judge, held that the territorial restriction clause was invalid. We accept their interpretation of the law.

Affirmed. *See*8th Cir.R. 14.
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.6040 Gene expression profiling test system for breast cancer prognosis. ( a ) *Identification.* A gene expression profiling test system for breast cancer prognosis is a device that measures the ribonucleic acid (RNA) expression level of multiple genes and combines this information to yield a signature (pattern or classifier or index) to aid in prognosis of previously diagnosed breast cancer.
( b ) *Classification.* Class II (special controls). The special control is FDA's guidance document entitled “Class II Special Controls Guidance Document: Gene Expression Profiling Test System for Breast Cancer Prognosis.” See § 866.1(e) for the availability of this guidance document.
[72 FR 26291, May 9, 2007]